Previous 10 | Next 10 |
2023-09-13 09:29:55 ET More on Mainz Biomed Seeking Alpha’s Quant Rating on Mainz Biomed B.V. Historical earnings data for Mainz Biomed B.V. Financial information for Mainz Biomed B.V. Mainz Biomed expands footprint in Germany with new partnership ...
2023-09-13 07:57:58 ET (24/7 MARKET NEWS) – Mainz Biomed N.V. (NASDAQ:MYNZ) reported, this morning, positive topline results from its ColoFuture study, a multi-center international clinical trial assessing the potential to integrate a portfolio of novel gene expression (mRNA) biomark...
Multiple novel mRNA biomarkers identified for potential integration into pivotal FDA PMA clinical trial (ReconAAsense) BERKELEY, Calif. and MAINZ, Germany, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a mol...
2023-09-05 04:23:39 ET Molecular genetics diagnostic company Mainz Biomed N.V. ( NASDAQ: MYNZ ) entered a strategic partnership with Ärztliches Labor Dr. Buhlmann, to strengthen its position in the German market. Given that ~0.5% of Germany's pop...
BERKELEY, Calif. and MAINZ, Germany, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a strategic partnership...
BERKELEY, Calif. and MAINZ, Germany, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today that Guido Baechler, Chief E...
BERKELEY, Calif. and MAINZ, Germany, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announces the commercial launch of ColoAle...
2023-08-15 11:35:38 ET Mainz Biomed B.V. press release ( NASDAQ: MYNZ ): 1H GAAP EPS of -$0.56. Revenue of $248,945 vs $139,240 in the year-ago quarter. H1 ColoAlert revenue rose 108% Y/Y. For further details see: Mainz Biomed B.V. GAAP EPS of -$0.56
ColoAlert ® Revenue Increases 108% Year Over Year in the First Six Months of 2023 ColoFuture and eAArly Detect Studies on Track to Report Results in September and in Q4, 2023 BERKELEY, Calif. and MAINZ, Germany, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Mainz Biomed...
2023-08-14 08:31:57 ET United States Steel ( X ) +28% explores strategic alternatives after rejecting Cleveland-Cliffs offer . AMC Entertainment Holdings ( APE ) +25% . Genius Group ( GNS ) +21% . Eloxx Pharmaceuticals ( ELOX ) +26% r ...
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- Mainz BioMed CEO Guido Baechler joined Steve Darling from Proactive to announce the company has submitted an application to the U.S. Food and Drug Administration requesting Breakthrough Device Designation for its innovative non-invasive Next Generation colorectal cancer sc...
On the basis of its positive clinical studies Mainz Biomed has now defined the final configuration including its novel mRNA biomarkers of the Next Generation Test to be used in pivotal registration study ReconAAsense A recent clinical analysis of this new configuration demonstrates sens...
BERKELEY, Calif. and MAINZ, Germany, July 02, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today reviewed its major accomplishments of the first six months ending June 30, 2024, and provided a cor...